Otros idiomas Xtacy Therapeutics Corp. Deutsche Boerse AG

Acciones

TT5

CA98423G1072

Mercado cerrado - Deutsche Boerse AG Otros sitios de cotización 08:07:59 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,0275 ^EUR	+150,00 %		+34,15 %	+120,00 %

17/04	Xtacy Therapeutics Corp. informa de los resultados del primer trimestre finalizado el 31 de diciembre de 2023	CI
15/04	Xtacy Therapeutics Corp. presenta los resultados del ejercicio cerrado el 30 de septiembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	17/04
Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	15/04
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs	06/12
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23/08/23
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18/04/23
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	03/04/23
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	29/03/23
Global Wellness Strategies Inc. Auditor Raises 'Going Concern' Doubt	29/03/23
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials	17/11/22
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings	31/10/22
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	02/09/22
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings	02/08/22
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	01/06/22
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update	12/05/22
Global Wellness Strategies Inc. Announces Appointment of Sud Agarwal as the Chief Medical Advisor	09/05/22
Global Wellness Strategies Inc. Announces Their Brand KaleidoMyco to Launch Their Proprietary Fizz Tablets	12/04/22
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	01/03/22
Global Wellness Strategies Inc. Announces the Addition of Two International Pedigreed Senior Advisors to Its Team and the Appointment of Meris Kott to the Board of Shanti Therapeutics	18/02/22
Global Wellness Strategies Inc. and iNGENü Sign Supply Agreement with PharmAla Biotech to Supply GMP MDMA	10/02/22
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	03/02/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Xtacy Therapeutics Corp. Deutsche Boerse AG

Acciones

TT5

CA98423G1072

Otros idiomas

Filtros